Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                News & Events for Human Drugs

News & Events for Human Drugs

                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective Home
          Drugs
          News & Events for Human Drugs
          Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches - 01/31/2024News & Events for Human Drugs Public
    Event Title
              Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches


                  January 31, 2024

  

    
  Share
    Post
    Linkedin

    Email
    PrintOn This Page
      Meeting InformationDate:
          
  


     
           

January 31, 2024   

 
 
        
                                      Time: 
                                      
9:00 AM
    - 4:30 PM
ET

 

     Attend
    Register for This Event
  Location

In-person and Virtual
	National Press Club
	529 14th St NW Washington DC 20045Meeting Background and Objective

Quality by design (QbD) and risk-based monitoring (RBM) approaches facilitate clinical trial modernization by enhancing efficiency without compromising data integrity or participant protections. The U.S. Food and Drug Administration (FDA) has encouraged the use of QbD and RBM through many outreach activities, such as co-hosting a public workshop in 2019 on implementing RBM approaches in clinical investigations.  FDA has also recently published several guidance documents on these topics, such as E6(R3) Good Clinical Practice, A Risk-Based Approach to Monitoring of Clinical Investigations – Questions and Answers, and E8(R1) General Considerations for Clinical Studies. Despite the efforts of FDA and other interested parties, QbD and RBM approaches to plan and conduct clinical investigations have not been fully utilized.  Additionally, as the COVID-19 pandemic necessitated changes to clinical trial design and conduct, recent experiences may help to inform the development of best practices for implementing QbD and RBM moving forward.  This public workshop, convened by Duke-Margolis Center for Health Policy under a cooperative agreement with the FDA, is an opportunity to facilitate a discussion among the clinical trials community and interested parties about challenges and successes of integrating QbD and RBM into the design and conduct of clinical studies.

The objectives of this meeting are to:

Encourage the incorporation of QbD principles into the design and conduct of clinical studies, including the development of study protocols and workflow processes
	Identify barriers to QbD and RBM implementation by sponsors, clinical research organizations, and clinical trial sites
	Inform best practices for incorporating QbD and RBM approaches into the design and conduct of clinical studiesFunding Acknowledgement

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD006807 totaling $3,193,089 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

For more information and to register for the workshop, please visit the Duke-Margolis event webpage.

                                                                                  Content current as of:
      11/27/2023
         
                   
Regulated Product(s)
		 DrugsMore Meetings,
      Conferences, and
      Workshops
        
        News & Events for Human Drugs

          
                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop